ClearBridge Investments - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.

Quarter-by-quarter ownership
ClearBridge Investments ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$81,765,784
-35.9%
2,293,570
-17.0%
0.08%
-31.3%
Q2 2023$127,468,532
+17.7%
2,763,246
+2.3%
0.12%
+11.7%
Q1 2023$108,313,175
-13.2%
2,701,077
+0.2%
0.10%
-16.3%
Q4 2022$124,833,498
+9.1%
2,694,442
-2.5%
0.12%
+7.0%
Q3 2022$114,408,000
-32.4%
2,762,822
-2.6%
0.12%
-27.2%
Q2 2022$169,264,000
-18.6%
2,837,143
-0.9%
0.16%
+1.3%
Q1 2022$207,978,000
-11.0%
2,863,921
+3.1%
0.16%
-1.9%
Q4 2021$233,674,000
+9.5%
2,778,859
+17.5%
0.16%
+4.6%
Q3 2021$213,355,000
-5.6%
2,365,621
-0.2%
0.15%
-3.2%
Q2 2021$226,029,000
+4.3%
2,370,520
+24.5%
0.16%
-3.1%
Q1 2021$216,721,000
-16.5%
1,903,395
+1.5%
0.16%
-19.4%
Q4 2020$259,600,000
+77.5%
1,875,317
+5.4%
0.20%
+59.5%
Q3 2020$146,214,000
+5.8%
1,778,978
+0.7%
0.13%
+0.8%
Q2 2020$138,180,000
+153.0%
1,766,562
+43.7%
0.12%
+111.9%
Q1 2020$54,618,000
+7.8%
1,229,310
+4.6%
0.06%
+40.5%
Q4 2019$50,688,000
-14.3%
1,175,774
-14.9%
0.04%
-19.2%
Q3 2019$59,112,000
-7.6%
1,381,777
+37.1%
0.05%
-5.5%
Q2 2019$64,000,000
-8.9%
1,007,873
-0.5%
0.06%
-11.3%
Q1 2019$70,281,000
+60.0%
1,013,273
+0.3%
0.06%
+40.9%
Q4 2018$43,916,000
-43.0%
1,010,036
+0.0%
0.04%
-33.3%
Q3 2018$77,094,000
+4.9%
1,009,872
+5.6%
0.07%
+10.0%
Q2 2018$73,519,000
+81.5%
956,412
+20.4%
0.06%
+57.9%
Q1 2018$40,516,000
+19663.9%
794,588
+17877.1%
0.04%
Q4 2017$205,000
-13.1%
4,420
-0.1%
0.00%
Q3 2017$236,000
-13.6%
4,425
+0.6%
0.00%
Q2 2017$273,000
+45.2%
4,397
+58.5%
0.00%
Q1 2017$188,000
-5.1%
2,775
-1.2%
0.00%
Q4 2016$198,000
+2.1%
2,810
+2.9%
0.00%
Q3 2016$194,000
+44.8%
2,730
-0.1%
0.00%
Q2 2016$134,000
+74.0%
2,732
+123.6%
0.00%
Q1 2016$77,000
+305.3%
1,222
+618.8%
0.00%
Q4 2015$19,0001700.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2023
NameSharesValueWeighting ↓
First Light Asset Management, LLC 441,159$39,788,0002.62%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 103,100$9,286,0002.24%
Rock Springs Capital Management LP 801,109$72,252,0001.52%
Avidity Partners Management LP 455,000$41,036,0000.91%
Motley Fool Asset Management LLC 134,357$12,118,0000.79%
FEDERATED HERMES, INC. 3,987,032$359,590,0000.68%
EMERALD ADVISERS, LLC 196,124$17,688,0000.64%
Ergoteles LLC 128,100$11,553,0000.42%
Tekla Capital Management LLC 140,726$12,692,0000.41%
Beck Bode, LLC 14,990$1,352,0000.38%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders